SCHEMBL4836049

SCHEMBL4836049

NC1c2ccsc2N=CN1c1ccc(NC(=O)Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PSEN1 P49768 3/20 0.46
▸ PSEN2 P49810 3/20 0.46
▸ APH1B Q8WW43 3/20 0.46
▸ NCSTN Q92542 3/20 0.46
▸ APH1A Q96BI3 3/20 0.46
▸ PSENEN Q9NZ42 3/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ MEN1 O00255 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ MAPK8 P45983 2/20 0.39
▸ LMNA P02545 2/20 0.38
▸ HTT P42858 2/20 0.38
▸ RHOC P08134 1/20 0.38
▸ RHOA P61586 1/20 0.38
▸ NTRK1 P04629 1/20 0.36
▸ MTOR P42345 1/20 0.35
▸ ROCK2 O75116 1/20 0.35
▸ NR2E1 Q9Y466 2/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4828962 0.86 CSF1R (0.39) MAPK8LMNAHTT
SCHEMBL4836423 0.86 KCNJ5 (0.36) MEN1MAPTKMT2AMAPK8LMNA
SCHEMBL4836549 0.85 RAB9A (0.46) MEN1MAPTKMT2AMAPK8SMN1; SMN2
SCHEMBL4825889 0.83 THRB (0.41) RHOCRHOA
SCHEMBL4825639 0.83 NTRK1 (0.39) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL4833602 0.82 PSEN1 (0.48) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL4825661 0.81 MAPT (0.48) MEN1MAPTKMT2ALMNAHTT
SCHEMBL4833604 0.80 MAPK8 (0.44) MEN1MAPTKMT2AMAPK8LMNA
SCHEMBL4825766 0.80 MAPK8 (0.47) MEN1KMT2AMAPK8NTRK1SMN1; SMN2
SCHEMBL4826378 0.79 CA12 (0.49) NTRK1ROCK2RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US claimed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP claimed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO claimed
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US disclosed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US disclosed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004142-A1 Chemical compounds TIE1, KDR, TEK PSEN1 2600/4885PSEN2 1266/4885APH1B 3144/4885
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR PSEN1 2399/4885PSEN2 942/4885APH1B 2132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback